Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best and safest dose of XL184 administered
orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated
in tumor formation, growth and migration. To determine the highest safe dose, subjects will
receive different amounts of the drug. The first group of subjects will receive the lowest
dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be
increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20
subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184
in this population.